AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...

Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His ...

Recursive self improvement (RSI) is the key to solving intelligence. Human intelligence is built on our ability to ...

Recursive self improvement is the key to solving intelligence. Human intelligence is built on our ability to characterize the ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...